Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: A pilot study

Psychosomatic Medicine

Volumn 64, Issue 5, 2002, Pages 835-840

  Modell, Jack G ^a   Boyce, Sarah ^a   Taylor, Eric ^a   Katholi, Charles ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antidepressant; Atopic dermatitis; Bupropion; Eczema; Psoriasis

Indexed keywords

AMFEBUTAMONE;

ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; PSORIASIS VULGARIS; SLEEP DISORDER; SUSTAINED RELEASE FORMULATION; TACHYCARDIA; VERTIGO;

ADULT; BUPROPION; DELAYED-ACTION PREPARATIONS; DERMATITIS, ATOPIC; DOPAMINE UPTAKE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 0036742335     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PSY.0000021954.59258.9B     Document Type: Article

References (54)

1. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Sulser F. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401.
2. Modell JG, May RS, Katholi CR. Effect of bupropion-SR on orgasmic dysfunction in non-depressed subjects. J Sex Marital Ther 2000;26:231-40.
3. Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. J Am Acad Dermatol 1994;31:613-6.
4. Berberian BJ, Breneman DL, Drake LA, Gratton D, Raimir SS, Phillips S, Sulica VI, Bernstein JE. The addition of topical doxepin to corticosteroid therapy: an improved treatment regimen for atopic dermatitis. Int J Dermatol 1991;38:145-8.
5. Hardman R, Hopkins EJ, Pye AM, Solomon M, Solomon S. A trial of imipramine in the treatment of psoriasis. J Coll Gen Pract 1965;10:315-6.
6. Hebel E. Psoriasisbehandling med imipramin. Ugeskr Laeger 1966;128:20-1.
7. Alpsoy E, Ozcan E, Cetin L, Ozgur O, Er H, Yilmaz E, Karaman T. Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? J Am Acad Dermatol 1998;38:197-200.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: The Association; 1994.
9. Diggle P, Liang K-Y, Zeger S, Analysis of longitudinal data. Oxford, UK: Oxford University Press; 1994.
10. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 1994;11:133-41.
11. Bassout A, Brinink A, Krauss J, Waldmeier P, Bischoff S. Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants. J Recept Res 1993;13: 341-54.
12. Gupta MA, Gupta AK, Ellis CN, Voorhees JJ. Some psychosomatic aspects of psoriasis. Adv Dermatol 1990;5:21-31.
13. Gupta MA, Gupta AK, Kirkby S, Weiner HK, Mace TM, Schork NJ, Johnson EH, Ellis CN, Voorhees JJ. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 1988;124:1052-7.
14. Ahmar H, Kurban AK. Psychological profile of patients with atopic dermatitis. Br J Dermatol 1976;95:373-7.
15. Fava GA, Perini GI, Santonastaso P, Fornasa CV. Life events and psychological distress in dermatologic disorders: psoriasis, chronic urticaria and fungal infections. Br J Med Psychol 1980; 53:277-82.
16. Ginsburg IH, Prystowsky JH, Kornfeld DS, Wolland H. Role of emotional factors in adults with atopic dermatitis. Int J Dermatol 1993;32:656-60.
17. Hashiro M, Okumura M. Anxiety, depression and psychosomatic symptoms in patients with atopic dermatitis: comparison with normal controls and among groups of different degrees of severity. J Dermatol Sci 1997;14:63-7.
18. Brown DG. Stress as a precipitant factor of eczema. J Psychosom Res 1972;16:321-7.
19. Gupta MA, Gupta AK, Schork NJ, Ellis CN. Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med 1994;56:36-40.
20. Cotterill JA. Psychophysiological aspects of eczema. Semin Dermatol 1990;9:216-9.
21. Neveu PJ, Castanon N. Is there evidence for an effect of antidepressant drugs on immune function? Adv Exp Med Biol 1999; 461:267-81.
22. Eisen JN, Irwin J, Quay J, Livnat S. The effect of antidepressants on immune function in mice. Biol Psychiatry 1989;26:805-17.
23. Audus KL, Gordon MA. Tricyclic antidepressant effects on the murine lymphocyte mitogen response. J Immunopharmacol 1982;4:13-27.
24. Basso AM, Depiante-Depaoli M, Cancela L, Molina V. Seven-day variable-stress regime alters cortical beta-adrenoceptor binding and immunologic responses: reversal by imipramine. Pharmacol Biochem Behav 1993;45:665-72.
25. Sacerdote P, Ciciliato IA, Rubboli F, Panerai AE. Effect of psychoactive drugs on lymphocyte neuropeptides. Ann N Y Acad Sci 1990;594:270-9.
26. Ravindran AV, Griffiths J, Merali Z, Anisman H. Lymphocyte subsets associated with major depression and dysthymia: modification by antidepressant treatment. Psychosom Med 1995;57: 555-63.
27. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001;21:199-206.
28. Stokes PE. The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Eur Neuropsychopharmacol 1995;5 Suppl 1:77-82.
29. Akil H, Haskett RF, Young EA, Grunhaus L, Kotun J, Weinberg V, Greden J, Watson SJ. Multiple HPA profiles in endogenous depression: effect of age and sex on cortisol and beta-endorphin. Biol Psychiatry 1993;33:73-85.
30. Mokrani MC, Duval F, Crocq MA, Bailey P, Macher JP. HPA axis dysfunction in depression: correlation with monoamine system abnormalities. Psychoneuroendocrinology 1997;22 Suppl 1:63-8.
31. Sabroe RA, Kennedy CT, Archer CB. The effects of topical doxepin on responses to histamine, substance P and prostaglandin E2 in human skin. Br J Dermatol 1997;137:386-90.
32. Charney DS, Heninger GR, Sternberg DE. Alpha-2 adrenergic receptor sensitivity and the mechanism of action of antidepressant therapy. The effect of long-term amitriptyline treatment. Br J Psychiatry 1983;142:265-75.
33. Golden RN, Rudorfer MV, Sherer MA, Linnoila M, Potter WZ. Bupropion in depression. I. Biochemical effects and clinical response. Arch Gen Psychiatry 1988;45:139-43.
34. Robinson DS, Johnson GA, Nies A, Corcella J, Cooper TB, Albright D, Howard D. Plasma levels of catecholamines and dihydroxyphenylglycol during antidepressant drug treatment. J Clin Psychopharmacol 1983;3:282-7.
35. Schildkraut JJ, Schatzberg AF, Samson JA, Rosenbaum A, Bowden CL. Norepinephrine output and metabolism in depressed patients during antidepressant treatments. Clin Neuropharmacol 1992;15 Suppl 1, Pt A:323-4.
36. Frazer A. Norepinephrine involvement in antidepressant action. J Clin Psychiatry 2000;61 Suppl 10:25-30.
37. Rupprecht M, Salzer B, Raum B, Hornstein OP, Koch HU, Riederer P, Sofic E, Rupprecht R. Physical stress-induced secretion of adrenal and pituitary hormones in patients with atopic eczema compared with normal controls. Exp Clin Endocrinol Diabetes 1997;105:39-45.
38. Thestrup-Pedersen K, Ellingsen AR, Olesen AB, Lund M, Kaltoft K. Atopic dermatitis may be a genetically determined dysmaturation of ectodermal tissue, resulting in disturbed T-lymphocyte maturation. A hypothesis. Acta Derm Venereol 1997;77:20-1.
39. Ring J, Dorsch W. Altered releasability of vasoactive mediator secreting cells in atopic eczema. Acta Derma Venereol Suppl 1985;114:9-23.
40. Hashiro M, Okumura M. The relationship between the psychological and immunological state in patients with atopic dermatitis. J Dermatol Sci 1998;16:231-5.
41. Archer CB, Hanson JM, Morley J, MacDonald DM. Adrenoceptor function in atopic dermatitis: in vitro and in vivo observations. Acta Derm Venereol Suppl 1985;114:93-7.
42. Reed CE, Busse WW, Lee TP. Adrenergic mechanisms and the adenyl cyclase system in atopic dermatitis. J Invest Dermatol 1976;67:333-8.
43. Schallreuter KU, Pittelkow MR, Swanson NN, Beazley WD, Korner C, Ehrke C, Buttner G. Altered catecholamine synthesis and degradation in the epidermis of patients with atopic eczema. Arch Dermatol Res 1997;289:663-6.
44. Ionescu G, Kiehl R. Increased plasma norepinephrine in psoriasis. Acta Derm Venereol 1991;71:169-70.
45. Schallreuter KU. Epidermal adrenergic signal transduction as part of the neuronal network in the human epidermis. J Invest Derm 1997;2:37-40.
46. Garcia-Castro M, Bronner-Fraser M. Induction and differentiation of the neural crest. Curr Opin Cell Biol 1999;11:695-8.
47. Thaller V, Vrkljan M, Hotujac L, Thakore J. The potential role of hypocortisolism in the pathophysiology of PTSD and psoriasis. Coll Antropol 1999;23:611-9.
48. Terui T, Ozawa M, Tagami H. Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop. Exp Dermatol 2000;9:1-10.
49. Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, Bliss JL, Schwertschlag U, Dorner AJ, Krueger JG. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999;104: 1527-37.
50. Espinoza LR, van Solingen R, Cuellar ML, Angulo J. Insights into the pathogenesis of psoriasis and psoriatic arthritis. Am J Med Sci 1998;316:271-6.
51. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999;135:1104-10.
52. Ionescu G, Kiehl R. Plasma catecholamine levels in severe atopic eczema. Allergy 1988;43:614-6.
53. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: s link to neurogenic skin disorders. Brain Behav Immun 1999;13:225-39.
54. Staniek V, Doutremepuich J, Schmitt D, Claudy A, Misery L. Expression of substance P receptors in normal and psoriatic skin. Pathobiology 1999;67:51-4.